Riskpilot← Back to searchSign inGet full accessGlycovisc Biotech AB
ABIn liquidationOrg 5565350005Other research and experimental development on natural sciences and engineering · NACE 7219Est. 19960 employees
Revenue 2022
SEK 0
EBITDA margin
—
-800% vs 2021
Equity ratio
100.0%
Financial strength
Net profit 2022
SEK -18K
-800% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -18K | -800% |
| Net profit | SEK -18K | -800% |
| Total assets | SEK 530K | -3% |
| Equity | SEK 530K | -3% |
| Employees | 0 | — |
Legal name
Glycovisc Biotech AB
Org number
5565350005
Legal form
Aktiebolag
NACE code
7219 · Other research and experimental development on natural sciences and engineering
Founded
22 oktober 1996
Share capital
SEK 500 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Bolaget skall bedriva utveckling, tillverkning och försäljning av läkemedel och andra medicinska produkter och därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 234 | −9 | −2 | −2 | −18 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 234 | −9 | −2 | −2 | −18 |
| Net financials | — | — | — | — | — |
| Profit before tax | 234 | −9 | −2 | −2 | −18 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 234 | −9 | −2 | −2 | −18 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 560 | 551 | 549 | 547 | 530 |
| Equity | 560 | 551 | 549 | 547 | 530 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | — | — | — | — | — |
EBITDA margin
-1800000.0%
This company
15.8%
Market median
-11392505% vs market
20182022
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182022
Return on equity
-3.4%
This company
18.4%
Market median
-118% vs market
20182022
Net profit margin
-1800000.0%
This company
8.1%
Market median
-22222322% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
HM External Signatory | External Signatory | 2022 |
CE External Signatory | External Signatory | 2022 |
BJ Liquidator | Liquidator | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Medivir Aktiebolag
Glycovisc Biotech AB Board members of Glycovisc Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Helena Margareta Jacobsson | External Signatory | 0 companies |
| Cecilia Elisabet Gradén | External Signatory | 0 companies |
| Bengt Junior Niklas Nygårds | Liquidator | 0 companies |
| Christina Elisabeth Herder | Deputy Board Member | 0 companies |
| Iain Edgar Dominey Morrison | Board of Directors | 0 companies |